Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28085501 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL3951046 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL3951048 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL9629265 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL1899147 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL15110985 | 0.94 | PRKCA (0.72) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL14730862 | 0.92 | PRKCA (0.58) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL14730832 | 0.92 | PRKCA (0.58) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL234818 | 0.91 | ENPP2 (0.69) | ENPP2LPAR3RECQLBLMTDP1 | |
| SCHEMBL2947211 | 0.91 | ENPP2 (0.69) | ENPP2LPAR3RECQLBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142775-A1 | TREATMENT OF NEURODEGENERATIVE CONDITIONS | BTG INTERNATIONAL LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-7964641-B2 | administering lipid glycerides for treating neurodegenerative disease such as multiple sclerosis; increasing transforming growth factors and tumor necrosis factors | BTG INTERNATIONAL LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-2324828-A1 | Treatment for neurodegenerative conditions | BTG International Limited (GB) | 2011-05-25 | — | — | EP | disclosed |
| US-20100113595-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20080194684-A1 | Treatment of Neurodegenerative Conditions | BTG INTERNATIONAL LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194684-A1 | Treatment of Neurodegenerative Conditions | LPAR2, DGAT2, DGKG | PRKCA 1032/4885PRKCE 906/4885PRKCQ 1522/4885 |
| US-20100113595-A1 | Treatment of neurodegenerative conditions | DGAT2, ALOX12, DGKG | PRKCA 1058/4885PRKCE 990/4885PRKCQ 1618/4885 |
| US-20120142775-A1 | TREATMENT OF NEURODEGENERATIVE CONDITIONS | DGAT2, ALOX12, DGKG | PRKCA 1058/4885PRKCE 990/4885PRKCQ 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.